Intravesical Chemotherapy Treatment of Superficial Bladder Cancer
Phase 2
Completed
- Conditions
- Bladder Neoplasms
- Registration Number
- NCT00491114
- Lead Sponsor
- Eli Lilly and Company
- Brief Summary
This is a phase II study where chemotherapy (gemcitabine) is given into the urinary bladder.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 8
Inclusion Criteria
- Superficial bladder cancer
- No prior chemotherapy
Exclusion Criteria
- Grade 3 tumors
- Papillary tumors invading connective tissue
- Significant urologic disease, possible interfering with intravesical therapy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method To evaluate the response rate
- Secondary Outcome Measures
Name Time Method To assess toxicity profile To define the relapse free survival
Trial Locations
- Locations (1)
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
🇮🇹Varese, Italy
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.🇮🇹Varese, Italy